Abiopharma

Graco Foundation Marks Company’s Centennial with $1 Million Commitment to Minnesota Nonprofits

Standard & Poor’s affirms the bank’s rating at BBB+ with a stable outlook

Alternative Ballistics Corporation to Present at the Small Cap Growth Virtual Investor Conference on June 4th

Deadline Soon: Pinterest, Inc. (PINS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Dormant shares - change in the number of shares

BeOne Medicines anuncia la publicación de los datos de fase 3 HERIZON-GEA en NEJM y su presentación en ASCO 2026

BeOne Medicines anuncia dados da Fase 3 do estudo HERIZON-GEA publicados no NEJM e apresentados na ASCO 2026

BeOne Medicines公布HERIZON-GEA第三期研究結果，刊登《NEJM》並於ASCO 2026發表

BeOne Medicines、HERIZON-GEA第3相試験データがNEJMに掲載、ASCO 2026で発表へ

BeOne Medicines annuncia i dati di fase 3 HERIZON-GEA pubblicati in NEJM e presentati allASCO 2026